ES2969605T3 - Composición veterinaria para rumiantes lecheros para el tratamiento de la fiebre de la leche - Google Patents
Composición veterinaria para rumiantes lecheros para el tratamiento de la fiebre de la leche Download PDFInfo
- Publication number
- ES2969605T3 ES2969605T3 ES21702017T ES21702017T ES2969605T3 ES 2969605 T3 ES2969605 T3 ES 2969605T3 ES 21702017 T ES21702017 T ES 21702017T ES 21702017 T ES21702017 T ES 21702017T ES 2969605 T3 ES2969605 T3 ES 2969605T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- dairy
- administered
- ruminants
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 241000282849 Ruminantia Species 0.000 title claims abstract description 63
- 235000013365 dairy product Nutrition 0.000 title claims abstract description 61
- 235000013336 milk Nutrition 0.000 title claims description 45
- 239000008267 milk Substances 0.000 title claims description 45
- 210000004080 milk Anatomy 0.000 title claims description 45
- 206010037660 Pyrexia Diseases 0.000 title claims description 23
- 238000011282 treatment Methods 0.000 title claims description 21
- 208000013038 Hypocalcemia Diseases 0.000 claims abstract description 42
- 230000000705 hypocalcaemia Effects 0.000 claims abstract description 42
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 241000283690 Bos taurus Species 0.000 claims description 41
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 40
- 229960004596 cabergoline Drugs 0.000 claims description 38
- 238000001035 drying Methods 0.000 claims description 13
- 241000283707 Capra Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 241000282817 Bovidae Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 32
- 239000011575 calcium Substances 0.000 description 32
- 229910052791 calcium Inorganic materials 0.000 description 32
- 239000008280 blood Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 24
- 230000006651 lactation Effects 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108090000445 Parathyroid hormone Proteins 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 6
- 102100036893 Parathyroid hormone Human genes 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 102000003946 Prolactin Human genes 0.000 description 4
- 108010057464 Prolactin Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940097325 prolactin Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 3
- 206010016326 Feeling cold Diseases 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960005084 calcitriol Drugs 0.000 description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 235000021277 colostrum Nutrition 0.000 description 3
- 210000003022 colostrum Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 208000018299 prostration Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Polymers CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000021045 dietary change Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000001184 hypocalcaemic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001263 anti-prolactin effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- -1 cabergoline Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940051921 muramidase Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008375 physiological alteration Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305067 | 2020-01-27 | ||
| PCT/EP2021/051767 WO2021151898A1 (en) | 2020-01-27 | 2021-01-26 | Veterinary composition for dairy ruminants for treatment of milk fever |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2969605T3 true ES2969605T3 (es) | 2024-05-21 |
Family
ID=69528717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21702017T Active ES2969605T3 (es) | 2020-01-27 | 2021-01-26 | Composición veterinaria para rumiantes lecheros para el tratamiento de la fiebre de la leche |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230346776A1 (https=) |
| EP (1) | EP4096429B1 (https=) |
| JP (1) | JP2023511187A (https=) |
| KR (1) | KR20220132558A (https=) |
| CN (1) | CN115038336B (https=) |
| AR (1) | AR122366A1 (https=) |
| AU (1) | AU2021214706A1 (https=) |
| BR (1) | BR112022014710A2 (https=) |
| CA (1) | CA3165994A1 (https=) |
| ES (1) | ES2969605T3 (https=) |
| HU (1) | HUE064770T2 (https=) |
| IL (1) | IL294910B2 (https=) |
| MX (1) | MX2022009178A (https=) |
| PL (1) | PL4096429T3 (https=) |
| UY (1) | UY39019A (https=) |
| WO (1) | WO2021151898A1 (https=) |
| ZA (1) | ZA202207860B (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| DE60023122T2 (de) * | 1998-10-30 | 2006-07-13 | Rj Innovation | Verfahren zur Verhinderung von Hypokalzämie in gebährenden Tieren und hierfür verwendete Zusammensetzungen |
| FR2936710B1 (fr) * | 2008-10-07 | 2011-01-07 | Ceva Sante Animale | Composition veterinaire antiprolactinique destinee aux ruminants |
| FR2971423B1 (fr) * | 2011-02-15 | 2014-01-10 | Ceva Sante Animale | Composition veterinaire antiprolactinique destinee aux ruminants |
| WO2019224149A1 (en) * | 2018-05-23 | 2019-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of an oral bolus in the drying-off of dairy cattle |
-
2021
- 2021-01-15 AR ARP210100105A patent/AR122366A1/es unknown
- 2021-01-15 UY UY0001039019A patent/UY39019A/es not_active Application Discontinuation
- 2021-01-26 HU HUE21702017A patent/HUE064770T2/hu unknown
- 2021-01-26 MX MX2022009178A patent/MX2022009178A/es unknown
- 2021-01-26 EP EP21702017.1A patent/EP4096429B1/en active Active
- 2021-01-26 ES ES21702017T patent/ES2969605T3/es active Active
- 2021-01-26 IL IL294910A patent/IL294910B2/en unknown
- 2021-01-26 JP JP2022544418A patent/JP2023511187A/ja active Pending
- 2021-01-26 BR BR112022014710A patent/BR112022014710A2/pt unknown
- 2021-01-26 KR KR1020227028049A patent/KR20220132558A/ko active Pending
- 2021-01-26 CA CA3165994A patent/CA3165994A1/en active Pending
- 2021-01-26 PL PL21702017.1T patent/PL4096429T3/pl unknown
- 2021-01-26 US US17/793,328 patent/US20230346776A1/en active Pending
- 2021-01-26 AU AU2021214706A patent/AU2021214706A1/en active Pending
- 2021-01-26 CN CN202180011764.9A patent/CN115038336B/zh active Active
- 2021-01-26 WO PCT/EP2021/051767 patent/WO2021151898A1/en not_active Ceased
-
2022
- 2022-07-14 ZA ZA2022/07860A patent/ZA202207860B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202207860B (en) | 2023-03-29 |
| WO2021151898A1 (en) | 2021-08-05 |
| MX2022009178A (es) | 2022-08-17 |
| JP2023511187A (ja) | 2023-03-16 |
| EP4096429C0 (en) | 2023-10-18 |
| IL294910A (en) | 2022-09-01 |
| IL294910B2 (en) | 2025-09-01 |
| US20230346776A1 (en) | 2023-11-02 |
| EP4096429A1 (en) | 2022-12-07 |
| HUE064770T2 (hu) | 2024-04-28 |
| IL294910B1 (en) | 2025-05-01 |
| AR122366A1 (es) | 2022-09-07 |
| CN115038336A (zh) | 2022-09-09 |
| CA3165994A1 (en) | 2021-08-05 |
| UY39019A (es) | 2021-07-30 |
| KR20220132558A (ko) | 2022-09-30 |
| CN115038336B (zh) | 2024-11-26 |
| PL4096429T3 (pl) | 2024-03-11 |
| BR112022014710A2 (pt) | 2022-10-11 |
| EP4096429B1 (en) | 2023-10-18 |
| AU2021214706A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2719844T3 (es) | Composición veterinaria antiprolactínica para rumiantes | |
| Garcia-Ispierto et al. | A three-day PGF2α plus eCG-based fixed-time AI protocol improves fertility compared with spontaneous estrus in dairy cows with silent ovulation | |
| Klopfenstein et al. | Diseases of the mammary glands | |
| Alexopoulos | Association of Fusarium mycotoxicosis with failure in applying an induction of parturition program with PGF2alpha and oxytocin in sows | |
| ES2969605T3 (es) | Composición veterinaria para rumiantes lecheros para el tratamiento de la fiebre de la leche | |
| Straw et al. | Influence of method of administration of prostaglandin on farrowing and relationship between gestation length and piglet performance | |
| Kuru et al. | Effect of two prostaglandin F2α injections administered 24 hours apart on the pregnancy rate of Simmental cows subjected to the Ovsynch or Ovsynch+ controlled internal drug release (CIDR) protocols. | |
| RU2842295C1 (ru) | Ветеринарная композиция для молочного жвачного животного для лечения молочной лихорадки | |
| US8048866B2 (en) | Preventive and/or therapeutic agent for calcipenia | |
| US20200375980A1 (en) | Veterinary antiprolactinic composition | |
| ES2969031T3 (es) | Composición antiprolactina veterinaria para rumiantes usada por administración intramamaria | |
| Javed et al. | Effects of reproductive hormones in dairy farm animals: reproductive hormones in dairy farm animals | |
| Zhu et al. | Cloprostenol sodium improves reproductive performance of multiparous sows during lactation | |
| Hossain et al. | Effect of Heat Stress on the Health and Performance of Dairy Cattle: A Comprehensive Review | |
| Metcalfe et al. | Medical treatment of pyometra and the use of aglepristone | |
| Guzmán et al. | Increased body condition score through increased lean muscle, but not fat deposition, is associated with reduced reproductive response to oestrus induction in beef cows | |
| RU2404728C1 (ru) | Способ повышения общей резистентности организма, профилактики и лечения респираторных, желудочно-кишечных и гинекологических заболеваний, профилактики эмбриональной смертности у животных и лекарственное средство для его осуществления | |
| RU2846098C1 (ru) | Ветеринарная антипролактиновая композиция для жвачных животных, используемая путем введения в молочную железу | |
| Cecchetto et al. | Pregnancy in a Female Ferret Following Treatment with a Deslorelin Implant: A Case Report | |
| ES2683868B1 (es) | Dinoprost Trometamina para incrementar la probabilidad de gestación en terneras | |
| Ninnasopha et al. | Comparison of progesterone implant and GnRH administration after insemination on pregnancy rate in dairy cows exposed to summer heat stress in Thailand. | |
| Larson et al. | Estrus synchronization and periconceptual supplementation affect the profitability of a replacement heifer enterprise | |
| MacGhee | The Role of Nutrition and Administration of Estrogen in Holstein Calf Growth, Development, and Adenogenesis | |
| Radostits | Take Home Messages | |
| Taşdemir et al. | The effect of progesterone based ovsynch protocol and gnrh treatment after artificial insemination on conception rate in repeat breeder cows |